Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing a development strategy that integrates biomedical literature analysis with therapeutic development, a focus it brought to Drug Discovery 2026 in Burlingame, California. At the conference, company executives Scott Myers and Saran Saund demonstrated how Oncotelic’s PDAOAI platform can help researchers organize scientific evidence and generate hypotheses for further investigation, according to the company’s presented materials.
Myers, Oncotelic’s Product Manager, delivered a presentation titled “The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development” on October 7. He described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. The platform aims to address the challenge of navigating vast amounts of scientific literature, enabling researchers to extract relevant insights more efficiently.
The following day, Saund, Chief Business Officer, presented an HCC case study that illustrated how disease-specific literature analysis led to a four-gene mTOR-related signature associated with survival. This signature was identified through an exploratory discovery analysis and validated in an independent Japanese cohort, underscoring the potential of AI-driven approaches to uncover clinically relevant biomarkers. The research highlights how Oncotelic is applying its platform to real-world therapeutic challenges, particularly in hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide.
Oncotelic also introduced BIO REBOOT, a program that connects the platform’s research capabilities with potential funding and development support for selected projects. This initiative aims to bridge the gap between discovery and commercialization, offering a pathway for promising research to advance toward clinical application. For investors, the news signals Oncotelic’s commitment to leveraging artificial intelligence to streamline drug development, a sector where efficient data analysis can significantly reduce time and costs.
The implications extend beyond Oncotelic. The PDAOAI platform’s ability to aggregate and analyze millions of abstracts could accelerate hypothesis generation across the biomedical field, potentially leading to new therapeutic targets and biomarkers. As the industry increasingly adopts AI tools, platforms like PDAOAI may become essential for researchers seeking to stay at the forefront of scientific discovery. The four-gene signature, if further validated, could also inform personalized treatment strategies for HCC patients, improving outcomes.
Oncotelic’s participation at Drug Discovery 2026 positions it among companies exploring the intersection of AI and drug development. The company’s newsroom, available at ibn.fm/OTLC, provides ongoing updates. For more details on the presentations, the full release is available through Read More>>.
InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers corporate communications solutions and social media distribution to help companies reach a wide audience.
